Exploring repositioning opportunities and side-effects of statins: a Mendelian randomization study of HMG-CoA reductase inhibition with 55 complex traits

Hon-Cheong SO^{1,2*}, Carlos Kwan-long Chau¹, Kai Zhao¹

¹School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong

²KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research of Common Diseases, Kunming
Zoology Institute of Zoology and The Chinese University of Hong Kong

*Correspondence to: Hon-Cheong SO, email: hcsso@cuhk.edu.hk

Abstract

Statin is one of the most commonly prescribed medications worldwide. Besides reduction of cardiovascular risks, statins have been proposed for the prevention or treatment of other disorders, but results from clinical studies are mixed. There are also controversies concerning the adverse effects caused by statins.

In this study we employed a Mendelian randomization (MR) approach across a wide range of complex traits to explore repositioning opportunities and side-effects of statins. MR is analogous to a “naturalistic” randomized controlled trial (RCT), which is much less susceptible to confounding and reverse causation as compared to observational studies.

We employed two genetic instruments (rs12916 and rs17238484) in the *HMGCR* gene which have been shown to provide reliable estimates of the risk of statins on type 2 diabetes and weight gain. We observed in the single- and joint-SNP analysis that low density lipoprotein cholesterol (LDL-C) reduction from HMG-CoA reductase inhibition results in increased depressive symptoms. This finding appeared to be supported by nominally significant results of raised major depression risk in single-SNP MR analysis of rs17238484, and analyses using LDL-C as the exposure. Several other outcomes also reached nominal significance ($p < 0.05$) in single- or joint-SNP analyses; for example, we observed causal associations of LDL-C lowering from HMG-CoA reductase inhibition with *reduced* risks of schizophrenia, anorexia nervosa, Alzheimer disease, Parkinson disease, as well as increased forearm bone mineral density, sleep duration and extreme longevity (highest q -value = 0.289). We also found evidence of casual relationships of LDL-C levels with schizophrenia, anorexia, sleep duration and longevity, following the same association directions as in analyses of *HMGCR* variants. These findings were at least partially supported by previous clinical studies. We did not observe associations with cognitive test profiles, renal outcomes, autoimmune diseases or cancers. While MR has its limitations and our findings remain to be confirmed in further studies, this work demonstrates the potential of a phenome-wide approach to reveal novel therapeutic indications and unknown drug side-effects.

INTRODUCTION

With the rising cardiovascular disease burden over the world, statins have become one of the most commonly prescribed classes of medications. For example, it was estimated that in the US over 25% (30 millions) of people were taking statins from 2005 to 2008¹. Statins act on the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase to reduce cholesterol synthesis, and there exist strong evidence that statins reduce cardiovascular risks²⁻⁴. Statins however are associated with side-effects such as myopathy, raised liver enzymes and increased risk of type 2 diabetes and probably hemorrhagic strokes⁵. There are also reports of statins being associated with other adverse effects, such as muscle-related symptoms other than myopathy⁶, cognitive decline⁷⁻⁹, mood changes or aggression^{10,11} and cataracts¹², but there is yet no conclusive evidence. On the other hand, statins have also been proposed as a treatment for other non-cardiovascular traits, for example in cancers¹³, neurological diseases¹⁴, infectious diseases¹⁵ and psychiatric disorders¹⁴. Since statins are very widely prescribed, understanding its side-effects as well as non-cardiovascular benefits and the corresponding mechanisms is of great public health importance. Also given the escalating cost in new drug development, repositioning of a relatively cheap medication like statin represents a cost-effective way of finding novel therapeutics.

Recently a few studies have been using a new approach known as Mendelian randomization (MR)¹⁶ to explore the efficacy or side-effects of medications^{1,17-21}. The principle is that genetic variants in the gene encoding the drug target act as “instruments” to reflect the actual drug action. A person having the lipid-lowering allele (or allelic score) at the relevant locus is analogous to receiving a lipid-lowering drug, and vice versa. The random allocation of alleles at conception is analogous to randomization in clinical trials. MR, when compared to conventional clinical studies, are much less susceptible to confounding bias and problems of reversed causality²². By studying genetic variations at the drug target, we may also infer whether the effects or side-effects are at least partially due to “on-target” mechanisms. MR therefore represents a promising approach to explore new indications and unintended adverse effects of drugs, as reported in a few recent studies. For example, Swerdlow et al. examined common variants in the *HMGCR* gene and found that the low density lipoprotein cholesterol (LDL-C) lowering allele is associated with higher body weight, waist circumference, insulin and glucose levels, as well as heightened type 2 diabetes risk. Remarkably, the results from this MR analysis are highly concordant with a meta-analysis of randomized controlled trial (RCT) of 129710 individuals¹. This study also demonstrated that raised diabetic risk is at last partially attributed to “on-target” effects of statins¹. Adopting a similar approach, Lotta et al. showed that SNPs in the *NPC1L1* and *HMGCR* genes (proxy for actions of ezetimibe and statins respectively) are both associated with elevated diabetic risks²¹. Another two MR studies on PCSK9 inhibition demonstrated similar findings of raised diabetic risks^{18,19}.

The MR approach can be extended to screen for associations of a larger variety of outcomes, also referred to as a “phenome-wide” scan. For instance, Millard et al. reported a phenome-wide MR study on BMI with 172 phenotypic outcomes, and found associations with cardiometabolic traits as well as novel associations

with global self-worth score²³. Another recent study investigated the effect of a loss-of-function variant in *PLA2G7* encoding lipoprotein-associated phospholipase A2 (Lp-PLA2), a drug target for atherosclerosis-related diseases, across 41 different non-vascular outcomes in the China Kadoorie Biobank²⁴. Overall no significant associations were found, implying a lack of major side-effects but also limited potential for repurposing²⁴. A recent commentary nicely summarizes the potential of using MR and a “phenome-wide” approach to facilitate drug discovery and reveal unknown drug side-effects²⁵.

In this study, we employ the principle of Mendelian randomization to explore repositioning opportunities and adverse effects of statins. Using variants of the *HMGCR* gene as instruments, we study the associations with up to 55 somatic and psychiatric traits, mainly on non-cardiovascular outcomes.

METHODS

Genetic instruments for effects of statins

We followed a previous landmark MR study which investigated the effects of HMG-CoA reductase inhibition on body-weight and type 2 diabetes risks¹. We used two SNPs (rs17238484 and rs12916) in the *HMGCR* gene as instruments that have been shown to provide reliable estimates of the risk of statins on type 2 diabetes and weight gain. The variant rs17238484 was used for the main analysis in Swerdlow et al., and the LDL-lowering G allele was associated with higher waist circumference, weight, insulin and glucose concentrations and type 2 diabetes risk¹. The effects were consistent with (and of comparable magnitude to) meta-analysis of RCTs covering 129170 participants. The other SNP allele rs12916-T had similar effects in general. As reported by Swerdlow et al., rs12916-T is also associated with significantly lower expression of *HMGCR* in the liver ($p = 1.3e-5$) but has no associations with expressions of neighboring genes¹. It was shown that this SNP likely drives the shared association between expression QTL and LDL-C levels¹. In addition, the two SNPs achieved genome-wide significance ($p < 5e-8$) in the Global Lipid Genetics Consortium (GLGC) meta-analysis²⁶ (Table 1). The effect sizes and standard errors of rs17238484 and rs12916 were extracted from meta-analysis results of the GLGC Metabochip studies. Note that the original GLGC study use inverse normal transformed trait values as the outcome variable, hence the coefficient estimate (approximately) corresponds to one SD change (~ 38.7 mg/dl or ~ 1 mmol/L) of LDL-C level per unit change in allelic count.

As the functional significance of *HMGCR* variants has not been fully elucidated (we do not know exactly which SNP or SNP combinations may represent the best proxy for the action of statins), we performed both single-SNP analyses (as in Swerdlow et al.¹) and a combined analysis of both SNPs. Note that as both SNPs are located in the *HMGCR* gene (*cis*-acting variants), they are likely to exert their effects via pathways related *HMGCR*, instead of through other mechanisms. Therefore we believe that horizontal pleiotropy is unlikely (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100611/>), although the small number of genetic markers does not allow more quantitative assessment of pleiotropy by methods like Egger regression or the weighted median approach.

Outcome data

We made use of the MR-base database and R package TwoSampleMR which collects GWAS summary statistics from mostly publicly available sources²⁷. A small percentage of the data available at MR-base were not openly available but obtained through communication with individual investigators. We performed analyses on several categories of complex traits or diseases as follows:

- (1) Psychiatric disorders or traits including anorexia nervosa, autism, bipolar disorder, bulimia nervosa, depressive symptoms, major depressive disorder (MDD), schizophrenia and sleep duration (for ;
- (2) Neurological disorders including Alzheimer's disease, amyotrophic lateral sclerosis and Parkinson's disease;
- (3) Renal traits or disorders including chronic kidney disease, microalbuminuria, IgA nephropathy; eGFR (creatinine) and urinary albumin to creatinine ratio (UACR) within diabetic subjects and within non-diabetic subjects;
- (4) Cancers including melanoma, pancreatic cancer, neuroblastoma, lung adenocarcinoma, squamous cell lung cell and lung cancer (irrespective of subtypes);
- (5) Autoimmune or inflammatory conditions including celiac disease, asthma, eczema, gout, Crohn's disease, ulcerative colitis, inflammatory bowel disease (combined), multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus;
- (6) Bone mineral density (BMD) measures including femoral neck, forearm and lumbar spine BMDs;
- (7) Hematological traits including haemoglobin (Hb) concentration, mean cell Hb, mean cell Hb concentration, mean cell volume, packed cell volume, red blood cell count, platelet count and mean platelet volume;
- (8) Neurocognitive test profiles including 2-choice, 4-choice and 8-choice reaction times, digit symbol, G speed factor, inspection time, simple reaction time and symbol search. This category is included due to previous reports of possible links between statin use and cognitive deficits (e.g. ref. ^{8,9});
- (9) Aging and longevity related traits including age of parents' death and top 1% survival in parents, which serve a proxy measure of longevity in the individual. The original study by Pilling et al.²⁸ explains the advantages of such an approach instead of recruiting very old cases and younger controls. An exact causal inference was not attempted here but the genetic variants or genetic score of the offspring can be regarded to reflect the genetically determined LDL-C-level (due to HMG-CoA reductase inhibition) of the parents. We aimed to test for a genetic (or polygenic) association with longevity similar to Marioni et al.²⁹. The effect size estimate is likely to be biased downwards as we are over-estimating the correlation between the genetic instruments and the risk factor (the denominator of an MR estimate).

A full list of references is included in supplementary information.

Statistical analysis

Mendelian randomization was performed with the Wald ratio test for individual SNP analyses and the inverse variance weighted (IVW) approach for analyses involving more than one SNP, which are default

methods employed in TwoSampleMR²⁷. If a SNP was not available in the outcome GWAS, we allowed using a “proxy SNP” provided the r-squared was at least 0.8 with the requested SNP. LD information was taken from the 1000 Genome European samples.

For the joint analyses of rs12916 and rs17238484, we accounted for the correlation using the method described in Burgess et al.³⁰. Briefly, assume $\hat{\beta}_{YG}$ to be the vector of estimated regression coefficients when the outcome is regressed on genetic instruments and σ_{YG} to be the corresponding standard errors (SE), and $\hat{\beta}_{XG}$ to be the estimated coefficients when the risk factor is regressed on the genetic instruments with SE σ_{XG} . We also assume the correlation between two genetic variants G_1 and G_2 to be $\rho_{G_1G_2}$, and $\Sigma_{G_1G_2} = \rho_{G_1G_2} \sigma_{YG_1} \sigma_{YG_2}$.

The estimate from a weighted generalized linear regression can be formulated by

$$\hat{\beta} = \left(\hat{\beta}'_{XG} \Sigma \hat{\beta}_{XG} \right)^{-1} \hat{\beta}'_{XG} \Sigma^{-1} \hat{\beta}_{YG}$$

with SE

$$SE(\hat{\beta}) = \sqrt{\left(\hat{\beta}'_{XG} \Sigma \hat{\beta}_{XG} \right)^{-1}}$$

We also performed the joint analysis by maximum likelihood estimation³¹ and the results were largely similar.

For a significant association of statins with a measured outcome, the association can be due to a general effect on LDL-C lowering, or more specifically due to HMG-CoA reductase inhibition. We therefore also examined the causal effects of LDL-C levels on outcomes having at least one nominally significant result. Totally 11 outcomes were studied. Genetic instruments for LDL-C were chosen according to the GLGC GWAS meta-analysis results²⁶. We included two sets of GWAS summary statistics, one from Metabochip and the other from joint GWAS and Metabochip analyses. (Note that in the study on *HMGCR* variants, we only considered results from Metabochip as one of the variants (rs17238484) was not reported in the latter joint analyses.)

We then performed further analyses to examine the causal effects of LDL-C on various outcomes. We again adopted the methodology by Burgess et al.³⁰ which is able to account for correlations among the instrument genetic variants. The method was based on formula (1) as described above. As remarked by the authors, inclusion of a bigger panel of variants in partial LD may enable higher variance to be explained, thus improving the power of MR. Including “redundant” SNPs in addition to the causal variant(s) do not improve power but also will not invalidate the results. However, including too many variants with high

correlations may also render the MR estimates unstable³². But there is a lack of strong theoretical justifications on the choice of a single specific r^2 threshold for analysis. We therefore attempted a range of thresholds, but controlled for multiple testing with FDR. We conducted MR analysis at four levels of r^2 threshold (0.05, 0.1, 0.15, 0.2) within a 10Mb region, using the IVW and Egger approach implemented in the R package “MendelianRandomization”, and accounted for SNP correlations at the same time. The intercept from Egger regression was used to assess whether there is significant directional pleiotropy (if $p < 0.05$). We primarily considered the results from IVW approach if there is no significant directional pleiotropy, otherwise the estimates from Egger regression were presented.

Multiple testing of different thresholds and the two GWAS datasets was corrected by the false discovery rate (FDR) approach with the Benjamini-Hochberg method³³, which controls the expected proportion of false discoveries. A q -value represents the minimum FDR at which an observed statistic can be called significant. In this study we set a primary FDR threshold of 0.05 to declare significance; results with $0.05 < q < 0.2$ were considered suggestive associations. Some of the test results were positively correlated due to overlapping genetic variants, but the FDR approach is also valid under positive (regression) dependencies³⁴. Correction by Bonferroni approach will be overly conservative due to correlations in hypotheses, in addition the Bonferroni approach controls the probability of making any single false discovery (to be < 0.05 usually), which have been argued to be too conservative in many settings³⁵. Here our aim is to discover potential casual relationships of statins or LDL-C with health traits, which are to be followed up or validated in further studies; controlling the proportion of false discoveries would fit this purpose. Moreover, the interpretation of Bonferroni-corrected tests depends on the number of tests performed, which can be subject to manipulations such as selective reporting to achieve the desired significance threshold³⁵.

RESULTS

The effect size estimates of the SNPs rs17238484 and rs12916 from GLGC and COJO-joint analysis are listed in Table 1. The alleles associated with *lower* LDL-C levels are designated as the effect alleles. Note that the coefficient estimates refer to the effect of *LDL-C lowering* due to HMG-CoA reductase inhibition.

Single-SNP analyses

For single-SNP analysis of rs17238484 (Table 2), a number of outcomes showed nominal significance, including anorexia nervosa (beta = -1.46, OR = 0.231, 95% CI = 0.068 to 0.786, $p = 0.019$), major depressive disorder (beta = 0.863, OR = 2.37, 95% CI = 1.06 to 5.34, $p = 0.037$), schizophrenia (beta = -0.496, OR = 0.609, 95% CI = 0.413 to 0.897, $p = 0.012$), sleep duration (beta = 0.186, 95% CI = 0.0378 to 0.334, $p = 0.014$), Alzheimer disease (beta = -0.797, OR = 0.450, 95% CI = 0.253 to 0.801, $p = 6.58e-3$), Parkinson disease (beta = -1.779, OR = 0.169, 95% CI = 0.035 to 0.803, $p = 0.025$), celiac disease (beta = 1.13, OR = 3.10, 95% CI = 1.04 to 9.18, $p = 0.042$) and forearm bone mineral density (beta = 0.719, 95% CI = 0.125 to 1.31, $p = 0.018$). The corresponding q -values ranged from 0.209 to 0.289. The results suggest

possible beneficial effects of genetically lower LDL-C from HMG-CoA reductase inhibition on the aforementioned diseases, except for MDD and celiac disease where the effects were towards increased risks. As an example, the results suggest that one SD (~ 38.7 mg/dl or ~ 1 mmol/L) decrease in LDL-C genetically due to HMG-CoA reductase inhibition leads to an increased risk of MDD by ~ 2-fold (OR = 2.37) and higher forearm bone density by 0.719 SD units. The other results may be interpreted in a similar manner.

Single-SNP analysis of rs12916 yielded three results with unadjusted $p < 0.05$ (Table 3), including depressive symptoms (beta = 0.129, 95% CI = 0.045 to 0.214, $p = 2.70 \times 10^{-3}$), platelet count (beta = -12.6, 95% CI = 0.458 to 24.7, $p = 0.042$) and top 1% survival (parental survival as proxy) (beta = 0.025, OR = 1.025, 95% CI = 1.00 to 1.05, $p = 0.048$). Of note, there was a trend towards significance for anorexia nervosa ($p = 0.063$); this trait also showed significant casual associations in single-SNP analysis of rs17238484.

Combined analysis of rs17238484 and rs12916

For the combined analysis of rs17238484 and rs12916, two outcomes achieved nominal significance ($p < 0.05$), including depressive symptoms (beta= 0.129, 95% CI = 0.045 to 0.214, $p = 2.77 \times 10^{-3}$, $q = 0.127$) and anorexia nervosa (beta = -0.901, OR = 0.406, 95% CI = -1.797 to -0.006, $p = 0.048$, $q = 0.822$). Top 1% survival showed a trend towards significance (beta = 0.024, OR = 1.024, 95% CI = 0.999 to 1.049, $p = 0.056$, $q = 0.822$) (Supplementary Table 1).

MR analysis of LDL-C with selected outcomes

We also performed MR analysis with LDL-C as the exposure for selected outcomes with nominal significant results (Table 4). Of note, the directions of associations from this analysis are fully concordant with the joint- and single-SNP analyses of *HMGCR*, except for celiac disease.

We observed significant associations of depressive symptoms and MDD. Lower LDL-C is causally linked to increased depressive symptoms (beta = 0.028, 95% CI 0.015 to 0.040, $p = 1.04 \times 10^{-5}$) and higher risk of MDD (OR = 1.15, 95% CI 1.07 to 1.23, $p = 9.31 \times 10^{-5}$) in this analysis. Both p-values passed the FDR control threshold at 0.05. We also observed potential causal relationship between lower LDL-C and reduced risk of schizophrenia (OR = 0.960, 95% CI 0.935 – 0.986, $p = 2.81 \times 10^{-3}$). Other significant associations included lower LDL-C with longer sleep duration, lower platelet count and risk of celiac disease. We also observed a link between lower LDL-C with top 1% parental survival. For anorexia nervosa, the association was suggestive with q-value < 0.1 . Low LDL-C was associated with reduced risk of anorexia. For Parkinson's disease and forearm bone density, we did not observe any significant associations, suggesting that for these traits any causal relationships with statins, if present, may be to a greater extent attributed to HMG-CoA reductase inhibition than to a general lowering effect of LDL-C.

For most outcomes the MR estimates were based on the IVW approach, except for celiac disease and top 1% parental survival where the estimates were derived from MR-Egger due to significant horizontal

pleiotropy. Full results are presented in Supplementary Table 2. Of note, for each trait under study, the directions of effects (provided that the result was at least nominally significant) were consistent despite different r^2 thresholds or dataset (joint or Metabochip only) used.

We noted a very recently published study¹⁷ which employed MR to study the effects of statins, PCSK9 inhibitors and LDL-C on AD and PD risks. The study initially reported that lower LDL is causally associated with reduced AD risk (genetic variants in APOE excluded), using summary statistics from GLGC and International Genomics of Alzheimer's Project (IGAP). Upon further analysis with a larger APOE gene region excluded, the authors revealed no significant causal relationships, which concurred with another recently published work in ophthalmology but used AD as a negative control³⁶. We did not pursue further analyses here as it appeared that the causal links between LDL-C and AD (as revealed from MR) may be contributed mainly by APOE region variants. However, this does not exclude the possibility that other specific mechanisms (which may be diluted when other variants are included as instruments), such as HMGCR inhibition, may exert an effect on AD.

DISCUSSION

In this study we have employed a Mendelian randomization approach to study the causal effects of genetically lowered LDL-C due to HMG-CoA reductase inhibition (analogous to the action of statins) on a large variety of traits. The analyses revealed several potential repositioning opportunities as well as adverse effects of statins. We shall discuss below associations showing at least nominal significance ($p < 0.05$) in our analyses.

Depression, statins and LDL-C levels

One important observation from this study is a potential causal link between genetically lower LDL-C from HMG-CoA reductase inhibition and increased depressive symptoms. Consistent with this observation, we also detected causal links of lower LDL-C levels with elevated MDD risk and depressive symptoms. Although there was ~10% overlap in the two samples, they were still largely different, and it is noteworthy that we observed significant *inverse* relationships between LDL-C and depression risk or symptom scores.

A number of studies have been performed to elucidate the relationships between cholesterol levels (including LDL-C), statins and depression, although the results were mixed. You et al.¹⁰ provided a detailed review of the evidence linking depression with low cholesterol levels and statin use. For example, low serum cholesterol has been reported to increased rates of suicide and increased depressive symptoms in a number of reports (e.g. ref.³⁷⁻⁴¹). Similarly, statin use has been suggested to be associated with elevated rates of depression (e.g. ref.⁴²⁻⁴⁵). The underlying mechanism remains to be elucidated, but some studies suggested that reduction of cholesterol may result in disruption of serotonin receptor functions¹⁰. For instance, Shrivastava et al. showed that chronic cholesterol depletion resulted in impaired ligand binding and G-protein coupling to serotonin 1A receptors⁴⁶. Another possible mechanism is through reduced synthesis of

neurosteroids⁴⁷, which are important for normal brain functioning such as synaptogenesis⁴⁸.

On the other hand, it has been postulated that the reduction of inflammatory responses by statins may contribute to antidepressant effects and some studies also found reduced depression risks among statin users⁴⁹. For example, a recent meta-analysis of 3 randomized controlled trials (RCTs) (total $N = 165$) revealed efficacy of statins in treating depression, although one should caution against the small sample size and number of studies⁵⁰. An earlier meta-analysis showed no significant differences in mental well-being between patients on statins or placebo, however there was high heterogeneity between the studies and psychological well-being were mainly assessed by self-report questionnaires⁵¹. There were also concerns of publications bias.

In the present study, we employed genetic instruments to model LDL-C levels, which reflect a life-long exposure to reduced LDL-C and it may not fully mimic the case of statin users. Therefore, it remains to be elucidated whether the observed effects on depressive symptoms from MR analyses can be directly translated to clinical practice. However, our results suggest that clinicians could be alerted to the possibility that development or exacerbation of depressive symptoms may be causally linked to prescription of statins or LDL-C lowering. For patients with risk factors for depression (*e.g.* family or past history of depression) who intend to receive or are receiving statins for prolonged periods, a greater awareness on mood changes and other psychiatric symptoms may be warranted.

Our results do not invalidate the possibility that statins may exert antidepressant properties under certain clinical scenarios. For example, significant results in RCTs⁵⁰ imply that a relatively short-term course of statin to ameliorate inflammatory responses may be beneficial for certain depressive patients. Further studies are required to clarify how the duration of statin treatment and patient characteristics (*e.g.* age, sex, presence of pre-existing depressive risk factors, cardiometabolic profiles, concomitant use of other medications like antidepressants etc.) may be associated with worsening or improvement of depressive symptoms.

Other psychiatric disorders and statins and LDL-C

For anorexia nervosa (AN), we observed relatively consistent results from single-SNP analysis of rs17238484 and rs12916, as well as from joint SNP analysis, that reduction of LDL-C from HMG-CoA reductase inhibition may reduce AN risk, although the statistical significance was not too strong. Concordantly, we also found suggestive associations between LDL-C and reduced risk of anorexia. Hypercholesterolemia, including raised LDL-C, is a well-known phenomenon in AN patients, although this association may appear paradoxical as these patients are generally malnourished and consume less fat than healthy individuals⁵². The underlying mechanism remains unclear. Although hypercholesterolemia is generally considered a consequence of AN, our results suggest that raised LDL (especially related to increased HMG-CoA reductase activity) may also be a casual risk factor for the disorder. Raised cholesterol synthesis has been suggested as a possible reason for hypocholesterolemia in these patients⁵³. Nevertheless, we

are not aware of any studies on the effects of statins in AN patients. Clinical observational studies and preferably RCTs are required before one can conclude the role of LDL-C and benefits of statins in these patients.

We also observed some evidence that statins may reduce schizophrenia risk from individual SNP analysis of rs17238484. In support of this finding, we detected potential causal effects of LDL-C on schizophrenia risks in the same direction. Statin has been proposed as a novel treatment for the disorder, presumably based on its potential to ameliorate neuroinflammation⁵⁴, and was tested in a small number of clinical trials. For instance, Vincenzi et al. reported improvement in the Positive and Negative Syndrome Scale (PANSS) from baseline to 6 weeks with pravastatin although the effect failed to maintain at 12 weeks⁵⁵. In another study, there was preliminary evidence that simvastatin improved PANSS scores, although the results were not statistically significant⁵⁶.

We found a slightly unexpected association of statin action with increased sleep duration in single-SNP MR analyses of rs17238484; interestingly, casual associations of reduced LDL-C with longer sleep duration was also detected. A limited number of observational studies suggested both short and long sleep durations are associated with lipid abnormalities^{57,58}, although the current analyses could not detect non-linear relationships. With regards to effects of statins on sleep, observational studies have found statins may be associated with sleep disturbances⁵⁹. However a recent meta-analysis of 5 RCTs ($N = 231$) showed that statins do not have adverse effects on sleep duration or efficiency⁶⁰. A more recent study reported significantly *lower* rate of sleep disturbance in patients assigned atorvastatin than those assigned placebo in a double-blind RCT setting⁶¹.

Neurological disorders and statins

Alzheimer disease (AD) is a common neurodegenerative disease for which few effective treatments are available. We found some evidence ($p = 6.58\text{e-}3$, $q = 0.256$) for statins to reduce AD risk from single-SNP MR analysis. The relationship between cholesterol lowering and statins with AD has been quite extensively studied. There is evidence from pre-clinical and clinical observational studies that statins may be able to prevent AD or mitigate the course of the disease^{14,62,63}. The results from RCTs were more mixed, and no conclusive benefits of statins can be ascertained yet^{64,65}. As with the study with other neuropsychiatric disorders, AD itself is a heterogeneous condition, and different patient characteristics (e.g. severity of illness, age, sex, comorbid illnesses etc.) in different studies may lead to mixed results. For Parkinson's disease (PD), there was only one matching SNP but the MR result was nominally significant ($p = 0.025$, $q = 0.274$). There is some evidence from animal⁶⁶ and observational studies (e.g. meta-analysis in ref.⁶⁷⁻⁶⁹) that statins may reduce PD risk.

A very recent study by Benn et al.¹⁷ also studied the *HMGCR* variant rs17238484 as a proxy for statin action in a Danish cohort. No associations were found with AD or PD, however the number of incident AD

and PD cases was relatively small (1001 and 460 respectively), which may have limited the power to detect significant associations. We have found preliminary evidence for beneficial effects of statins in this study, but further studies are required to confirm the findings.

It is also worth mentioning that there are concerns about cognitive impairment as a side-effect of statins⁷⁰. Besides studying AD, we also included a panel of cognitive test profiles as outcomes but did not find any significant associations. Although there is a chance of false negatives, this study and the previous work by Benn et al.¹⁷ appeared to show no causal relationship between statins and cognitive impairment.

Longevity and statins

We also revealed a potential polygenic association of *HMGCR* variants with extreme longevity (top 1% survival) and a highly significant association of LDL-C polygenic score with this trait (lowest $p = 8.43 \times 10^{-9}$). The association is probably at least partially attributed to reduction in cardiovascular events. It remains unclear whether and by how much statins or reduction in LDL-C will benefit survival. A microsimulation study predicted that statin therapy is associated with an increased life expectancy of 0.3 years⁷¹. Our point OR estimate for extreme longevity was also relatively small for joint SNP analysis in *HMGCR* (OR = 1.024, 95% CI 0.999-1.049) and for LDL-C (OR = 1.016, 95% CI 1.012 to 1.019), although as explained above the estimate might be biased downwards.

Other possible associations

We observed a nominally significant association of increased forearm bone mineral density (BMD) with *HMGCR* variant. Statins are postulated to stimulate bone formation and hence improve BMD^{72,73}. A recent meta-analysis of RCTs reported a small but significant benefit on BMD but no effects on fracture risk⁷⁴. As we only detected a positive association for forearm BMD but not at two other sites (femoral neck and lumbar spine), the findings should be viewed with caution. Another nominal association was a potential decrease in platelet count with statins; we also reported a significant association of lower LDL-C with reduced platelet count. We did not find evidence from the literature that statins reduce platelet levels, although there might be an effect on reducing platelet aggregation⁷⁵ and mean platelet volume⁷⁶, which in turn might confer cardiovascular benefits. Limited evidence suggests a relationship between lower platelet counts and reduced cardiovascular risks⁷⁷. Another nominal association was with celiac disease; again we did not find support from previous studies of any relationship between statins and celiac disease, except one study which showed that atorvastatin had no effect on gluten-induced production of inflammatory cytokines in intestinal biopsies⁷⁸.

Negative findings

While a number of findings are negative, given the very widespread use of statins, these negative results are probably also of important public health significance. We did not find evidence that statins improve renal outcomes from MR analysis. A Cochrane review showed consistently lower mortality and cardiovascular

events in chronic kidney disease (CKD) patients not requiring dialysis, but the effect on kidney function was inconclusive⁷⁹. A more recent meta-analysis however showed beneficial effects of high-intensity statin therapy on estimated glomerular filtration rate (eGFR), while moderate- or low-intensity treatment did not show benefits⁸⁰. Our negative findings may be due to statins only having an effect in a subgroup of patients with high-intensity therapy (which may be beyond the lipid-lowering effect of the studied genetic instruments). Alternatively, such beneficial effects may be due to off-target mechanisms. Similarly, no associations with cancers were found. There is currently no strong evidence to support chemopreventive potential of statins against most cancers^{81,82}. Our results suggest that statins did not reduce or increase cancer risks. The current analysis, however, is limited by a relative lack of GWAS summary statistics available for cancers and relatively moderate sample sizes for some datasets. Finally, there were no associations found with autoimmune diseases. Parallel to this finding, there is lack of high-quality observational studies or RCTs demonstrating clear benefits of statins on the treatment of autoimmune disorders, although pre-clinical studies suggested statins may be useful for certain autoimmune diseases⁸³. On the other hand, our results do not support the claim that statins may be a risk factor for autoimmune disorders in previous reports⁸⁴.

We provided a discussion regarding our significant results with unadjusted $p < 0.05$ above, and noted many associations were supported by previous pre-clinical or clinical studies. Nevertheless, some of the findings could represent false positives (we also provided estimates of FDR in this report), and care must be taken before application of any results to clinical settings. Due to various limitations of an MR approach, we believe that the results did not yet provide confirmatory evidence for the repositioning potential or adverse effects of statins in actual practice, and further large-scale studies especially RCTs are needed to confirm the findings.

Strengths and Limitations

This is the first study to employ a “phenome-wide” MR approach to explore drug repositioning opportunities and adverse side effects of statins and of a commonly used medication. The MR approach is analogous to a “naturalistic” RCT which is much less susceptible to confounding and reverse causation compared to clinical observational studies. This phenome-wide analysis provides an unbiased and comprehensive assessment of the therapeutic potential and side-effects of statins.

This study has several limitations. Firstly, as discussed previously, we employed genetic instruments to model the risk factor, reflecting a life-long exposure to altered LDL-C levels. Statin users typically receive the drug for a shorter period of time, and whether the effects of statins will be similar to those observed in the MR analyses requires further investigation via clinical studies. In addition, we focused on *HMGCR* variants which modelled the “on-target” effects of statins on HMG-CoA reductase (and its downstream pathways⁸⁵). Off-targets effects might be missed. In a similar vein, we focused on a common mechanism of action by all statins, but it is possible that individual statins may exert more specific effects that are currently unknown. Pharmacokinetic properties of different statins, including ability to cross the blood-brain barrier,

will need to be considered before applying specific statins for drug repositioning. Another potential limitation is that current GWAS mainly focus on identifying susceptibility variants for the development of disease, but few investigated the genetic basis underlying disease progression. As a result, MR analyses with drug target genes may be able to detect drugs potentially useful for disease prevention, but their effects on altering disease progression is less certain⁸⁶. Nonetheless, a drug can be useful both in prevention and altering the disease course or preventing relapses, as is the case for statins for coronary heart disease⁸⁷. A recent commentary⁸⁶ provided a discussion on this issue. Also, the power of the MR analysis depends on the sample size of the GWAS studies, for several traits in our analysis (e.g. neurocognitive profiles and several cancers) the sample sizes are relatively modest and false negative results are possible.

Another potential source of bias is the collider bias, which in this study involves GWAS datasets of the UK Biobank (UKB). This issue has been recently discussed in Munafo et al.⁸⁸. Briefly, there is evidence of “healthy volunteer bias” among UKB participants and the sample was healthier than the general UK population⁸⁹. If an exposure and an outcome both influence the probability of participation, spurious associations between the two may result, as exposure and outcome are both conditioned on ‘participation’, or the collider in this case. In our current study, only a few GWAS involved the UK BioBank. For the GWAS on depressive symptoms⁹⁰, ~58% of the sample was recruited from the UK BioBank. Although we did not have data on the rates of hyperlipidemia in UKB, a recent study reported much lower rates of cardiovascular diseases and risk factors (e.g. high blood pressure, diabetes) among UKB subjects⁸⁹. It is probably reasonable to expect low LDL and low depressive symptoms are both linked to higher chance of participation in UKB; collider bias will lead to a positive association between low LDL and reduced depressive symptoms. Since we now observed causal relationships in the *opposite* direction, the findings cannot be explained by collider bias. In addition, a concordant causal link (lower LDL-C causing increased depression) was detected when we considered the PGC-MDD⁹¹ sample alone. Sleep duration was also extracted from UKB data, but there is no strong justification to believe that this variable has substantial impact on participation, nevertheless we cannot exclude possibility of collider bias. Yet another trait, top 1% survival in parents, may be more subject to this bias. Longevity in parents leads to longevity in offspring, and this factor along with low LDL may both be linked to participation in UKB, which may create a positive bias in the association between the two variables.

In summary, we showcased a phenome-wide MR approach to uncover repositioning opportunities and side-effects for statins. A number of findings, such as potential adverse effects on depressive symptoms and repositioning potential for several neuropsychiatric disorders, are worthy of further investigation. On the other hand, negative findings might also be of value due to the very widespread use of the drug. We hope that further preclinical experiments, clinical studies and RCTs will help to follow up and verify our findings.

Acknowledgements

This study is partially supported by the Lo-Kwee Seong Biomedical Research Fund and a Direct Grant from

the Chinese University of Hong Kong. We would like to thank the Hong Kong Bioinformatics Center for computing support.

Author contributions

HCS designed, conceived and led the study. HCS performed the main data analysis, with assistance from CKLC and KZ. HCS interpreted the results and wrote the manuscript.

Conflicts of interest

The author declares no conflict of interest.

Table 1 SNPs used as genetic instruments in Mendelian randomization analysis

chr	SNP	effect_allele (lipid-lowering)	other_allele	beta	se	<i>p</i>
5	rs12916	T	C	0.0695	0.0053	1.79E-34
5	rs17238484	G	T	0.0627	0.0062	1.47E-21

Effect sizes are extracted from meta-analysis performed by the Global Lipid Genetics Consortium. Beta: regression coefficient; se, standard error; eaf, effect allele frequency; beta_joint and se_joint, coefficient and standard error estimate from COJO-joint analysis.

Table 2 Mendelian randomization analysis of *HMGR* variant rs17238484

Outcome	N	b (lower LDL)	se	p	qval
Psychiatric disorders/traits					
Anorexia nervosa GCAN 2014	17767	-1.462	0.623	0.019	0.209
Autism PGC 2015	10263	-0.341	0.522	0.513	0.825
Bipolar disorder PGC 2011	16731	-0.214	0.450	0.634	0.850
Bulimia nervosa 2013	2442	0.080	0.144	0.579	0.850
Depressive symptoms SSGAC 2016	161460	0.048	0.064	0.453	0.825
Major depressive disorder PGC 2013	18759	0.863	0.413	0.037	0.289
Schizophrenia PGC 2014	82315	-0.496	0.198	0.012	0.209
Sleep duration UK Biobank 2016	128266	0.186	0.075	0.014	0.209
Neurological disorders					
Alzheimer's disease IGAP 2013	54162	-0.797	0.293	6.58E-03	0.209
Amyotrophic lateral sclerosis Project MinE 2016	36052	-0.212	0.333	0.525	0.825
Parkinson's disease 2009	5691	-1.779	0.796	0.025	0.229
Renal disorders					
Chronic kidney disease CKDGen 2015	118142	-0.207	0.287	0.470	0.825
IgA nephropathy 2010	5983	2.437	1.638	0.137	0.825
Microalbuminuria CKDGen 2015	54116	0.323	0.498	0.517	0.825
<i>Within DM subjects</i>					
Urinary albumin-to-creatinine ratio CKDGen 2015	5825	-0.351	0.542	0.518	0.825
Serum creatinine (eGFRcrea) CKDGen 2015	11522	-0.067	0.070	0.340	0.825
<i>Within non-DM subjects</i>					
Urinary albumin-to-creatinine ratio CKDGen 2015	46061	-0.120	0.121	0.324	0.825
Serum creatinine (eGFRcrea) CKDGen 2015	118354	0.003	0.018	0.856	0.923
Cancer					
Lung adenocarcinoma ILCCO 2014	18336	0.513	0.502	0.307	0.825
Lung cancer ILCCO 2014	27209	0.271	0.333	0.415	0.825
Melanoma MDACC 2011	2824	-0.929	1.092	0.395	0.825
Neuroblastoma 2013	4881	-0.502	0.870	0.563	0.850
Pancreatic cancer PanScan1 2009	3835	-0.406	1.033	0.694	0.850
Squamous cell lung cancer ILCCO 2014	18313	0.238	0.509	0.640	0.850
Autoimmune/inflammatory					
Asthma GABRIEL 2007	26475	0.316	0.374	0.399	0.825

Celiac disease 2010	15283	1.130	0.555	0.042	0.289
Crohn's disease IIBDGC 2015	20883	0.383	0.427	0.371	0.825
Eczema EAGLE 2014	40530	-0.152	0.318	0.632	0.850
Gout GUGC 2013	69374	0.718	0.622	0.249	0.825
Inflammatory bowel disease IIBDGC 2015	34652	0.285	0.314	0.364	0.825
Multiple sclerosis MSGC 2013	38589	0.206	0.313	0.511	0.825
Rheumatoid arthritis 2014	58284	-0.159	0.242	0.512	0.825
Systemic lupus erythematosus 2008	3094	1.057	0.898	0.239	0.825
Ulcerative colitis IIBDGC 2015	27432	0.128	0.399	0.749	0.858

Bone

Femoral neck bone mineral density GEFOS 2015	49988	-0.022	0.143	0.879	0.930
Forearm bone mineral density GEFOS 2015	10805	0.719	0.303	0.018	0.209
Lumbar spine bone mineral density GEFOS 2015	44731	-0.060	0.166	0.718	0.850

Haematological

Haemoglobin concentration HaemGen 2012	54908	0.040	0.108	0.713	0.850
Mean cell haemoglobin HaemGen 2012	47229	-0.011	0.188	0.953	0.953
Mean cell haemoglobin concentration HaemGen 2012	50336	-0.056	0.065	0.393	0.825
Mean cell volume HaemGen 2012	51903	0.128	0.482	0.791	0.888
Mean platelet volume HaemGen 2011	19261	-0.011	0.021	0.590	0.850
Packed cell volume HaemGen 2012	52758	0.440	0.338	0.193	0.825
Platelet count HaemGen 2011	66867	-3.045	7.579	0.688	0.850
Red blood cell count HaemGen 2012	49103	0.027	0.041	0.513	0.825

Cognitive tests

2-choice reaction time 2011	2602	0.506	0.512	0.323	0.825
4-choice reaction time 2011	2829	0.611	0.518	0.239	0.825
8-choice reaction time 2011	1382	-0.526	0.750	0.483	0.825
Digit symbol 2011	2956	-0.388	0.491	0.430	0.825
G speed factor 2011	2430	0.056	0.558	0.920	0.937
Inspection time 2011	2645	-0.123	0.523	0.814	0.895
Simple reaction time 2011	2378	0.179	0.510	0.726	0.850
Symbol search 2011	991	0.303	0.839	0.718	0.850

Aging and Longevity

Parents' age at death UK Biobank 2016	75244	-0.015	0.143	0.916	0.937
Top 1 % survival UK Biobank 2016	75244	0.017	0.016	0.288	0.825

N , sample size; b (lower LDL), effect size (coefficient) estimate of having lower LDL cholesterol; $qval$, q -value. Nominally significant results (unadjusted $p < 0.05$) are in bold. NA, not available.

Table 3 Mendelian randomization analysis of *HMGCR* variant rs12916

Outcome	<i>N</i>	b (lower LDL)	se	<i>p</i>	qval
Psychiatric disorders/traits					
Anorexia nervosa GCAN 2014	17767	-0.851	0.458	0.063	0.632
Autism PGC 2015	10263	-0.413	0.403	0.305	0.925
Bipolar disorder PGC 2011	16731	-0.336	0.353	0.341	0.925
Bulimia nervosa 2013	2442	0.014	0.101	0.886	0.967
Depressive symptoms SSGAC 2016	161460	0.129	0.043	2.70E-03	0.130
Major depressive disorder PGC 2013	18759	0.425	0.312	0.173	0.923
Schizophrenia PGC 2014	82315	-0.078	0.154	0.613	0.941
Sleep duration UK Biobank 2016	128266	0.029	0.058	0.617	0.941
Neurological disorders					
Alzheimer's disease IGAP 2013	54162	-0.068	0.236	0.774	0.953
Amyotrophic lateral sclerosis Project MinE 2016	36052	0.173	0.259	0.505	0.941
Renal disorders					
Chronic kidney disease CKDGen 2015	118142	-0.014	0.230	0.950	0.999
Microalbuminuria CKDGen 2015	54116	0.273	0.302	0.366	0.925
<i>Within DM subjects</i>					
Urinary albumin-to-creatinine ratio CKDGen 2015	5825	-0.201	0.417	0.629	0.941
Serum creatinine (eGFR _{crea}) CKDGen 2015	11522	-0.003	0.053	0.957	0.999
<i>Within non-DM subjects</i>					
Urinary albumin-to-creatinine ratio CKDGen 2015	46061	0.013	0.091	0.886	0.967
Serum creatinine (eGFR _{crea}) CKDGen 2015	118354	0.006	0.013	0.664	0.941
Cancer					
Lung adenocarcinoma ILCCO 2014	18336	0.171	0.397	0.666	0.941
Lung cancer ILCCO 2014	27209	0.249	0.256	0.331	0.925
Squamous cell lung cancer ILCCO 2014	18313	0.243	0.393	0.537	0.941
Autoimmune/inflammatory					
Celiac disease 2011	24268	-0.115	0.282	0.684	0.941
Crohn's disease IIBDGC 2015	20883	-0.127	0.335	0.706	0.941
Eczema EAGLE 2014	40530	-0.172	0.245	0.484	0.941
Gout GUGC 2013	69374	0.446	0.475	0.348	0.925

Inflammatory bowel disease IIBDGC 2015	34652	0.042	0.247	0.866	0.967
Multiple sclerosis MSGC 2013	38589	0.425	0.242	0.079	0.632
Rheumatoid arthritis 2014	58284	0.143	0.181	0.429	0.941
Ulcerative colitis IIBDGC 2015	27432	0.119	0.314	0.704	0.941

Bone

Femoral neck bone mineral density GEFOS 2015	49988	0.018	0.115	0.878	0.967
Forearm bone mineral density GEFOS 2015	10805	0.264	0.232	0.255	0.925
Lumbar spine bone mineral density GEFOS 2015	44731	0.085	0.129	0.509	0.941

Haematological

Haemoglobin concentration HaemGen 2012	54908	-0.096	0.086	0.264	0.925
Mean cell haemoglobin HaemGen 2012	47229	0.193	0.153	0.206	0.925
Mean cell haemoglobin concentration HaemGen 2012	50336	-0.030	0.052	0.560	0.941
Mean cell volume HaemGen 2012	51903	0.694	0.391	0.076	0.632
Mean platelet volume HaemGen 2011	19261	0.009	0.016	0.585	0.941
Packed cell volume HaemGen 2012	52758	-0.075	0.256	0.770	0.953
Platelet count HaemGen 2011	66867	-12.557	6.173	0.042	0.632
Red blood cell count HaemGen 2012	49103	-0.050	0.033	0.128	0.828

Cognitive tests

2-choice reaction time 2011	2602	0.593	0.400	0.138	0.828
4-choice reaction time 2011	2829	-0.004	0.410	0.992	1.000
8-choice reaction time 2011	1382	0.000	0.590	1.000	1.000
Digit symbol 2011	2956	-0.165	0.387	0.669	0.941
G speed factor 2011	2430	0.515	0.437	0.239	0.925
Inspection time 2011	2645	-0.101	0.412	0.807	0.967
Simple reaction time 2011	2378	0.265	0.400	0.508	0.941
Symbol search 2011	991	0.225	0.656	0.732	0.950

Aging and Longevity

Parents' age at death UK Biobank 2016	75244	-0.104	0.110	0.344	0.925
Top 1 % survival UK Biobank 2016	75244	0.025	0.013	0.048	0.632

Nominally significant results (unadjusted $p < 0.05$) are in bold. Please refer to legends of Table 2.

Table 4 Mendelian randomization analysis using LDL-C as exposure

Outcome	Sample size	r ² thres	Metabochip /joint	Pleiotropy pval	Beta (lower LDL)	SE	95% CI Lower	95% CI Upper	pval (Egger if pleiotropy +ve)	MR method	qval
Anorexia nervosa GCAN 2014	17767	0.15	Metabochip	0.260	-0.202	0.078	-0.354	-0.049	9.61E-03	IVW	<i>7.69E-02</i>
Depressive symptoms SSGAC 2016	161460	0.1	jointGWAS	0.161	0.028	0.006	0.015	0.040	1.04E-05	IVW	8.32E-05
Major depressive disorder PGC 2013	18759	0.15	jointGWAS	0.671	0.140	0.036	0.070	0.210	9.31E-05	IVW	7.45E-04
Schizophrenia PGC 2014	82315	0.2	jointGWAS	0.123	-0.041	0.014	-0.067	-0.014	2.81E-03	IVW	1.96E-02
Sleep duration UK Biobank 2016	128266	0.2	Metabochip	0.820	0.034	0.007	0.021	0.047	2.36E-07	IVW	1.89E-06
Parkinson's disease NA 2009	5691	0.1	Metabochip	0.308	0.273	0.162	-0.045	0.590	9.22E-02	IVW	5.16E-01
Platelet count HaemGen 2011	66867	0.2	jointGWAS	0.930	-3.274	0.846	-4.931	-1.616	1.08E-04	IVW	8.64E-04
Forearm bone mineral density GEFOS 2015	10805	0.15	jointGWAS	0.927	-0.048	0.024	-0.096	0.000	5.00E-02	IVW	3.49E-01
Celiac disease NA 2010	15283	0.15	jointGWAS	0.001	-0.289	0.096	-0.477	-0.102	2.52E-03	Egger	2.02E-02
Top 1 % survival UK Biobank 2016	75244	0.2	jointGWAS	8.78E-05	0.016	1.75E-03	0.012	0.019	5.69E-19	Egger	4.55E-18

Here we present the best result for each trait considering different r² thresholds and the use of different GWAS datasets (Metabochip or jointGWAS), with multiple testing controlled by FDR. All effect sizes refer to the effect of having *lower* LDL-C. IVW: inverse variance weighted method; Egger, MR-Egger method; pleiotropy *p*, p-value from test of unbalanced horizontal pleiotropy by the MR-Egger method; qval, q-values. Q-values < 0.05 are in bold; suggestive associations (0.05 < *q* < 0.2) are in italics. Please refer to Supplementary Table 2 for full results.

References

1. Swerdlow, D.I. *et al.* HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. *Lancet* **385**, 351-361 (2015).
2. Kearney, P.M. *et al.* Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet* **371**, 117-125 (2008).
3. Baigent, C. *et al.* Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. *Lancet* **376**, 1670-1681 (2010).
4. Mihaylova, B. *et al.* The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet* **380**, 581-590 (2012).
5. Collins, R. *et al.* Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet* **388**, 2532-2561 (2016).
6. Buettner, C. *et al.* Statin Use and Musculoskeletal Pain Among Adults With and Without Arthritis. *American Journal of Medicine* **125**, 176-182 (2012).
7. US Food and Drug Administration. FDA Drug Safety Communication 2012: Important safety label changes to cholesterol-lowering statin drugs. (accessed 29th July, 2017).
8. Muldoon, M.F., Ryan, C.A., Sereika, S.A., Flory, J.D. & Manuck, S.B. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. *American Journal of Medicine* **117**, 823-829 (2004).
9. Evans, M.A. & Golomb, B.A. Statin-Associated Adverse Cognitive Effects: Survey Results from 171 Patients. *Pharmacotherapy* **29**, 800-811 (2009).
10. You, H., Lu, W., Zhao, S.P., Hu, Z.P. & Zhang, J.N. The relationship between statins and depression: a review of the literature. *Expert Opinion on Pharmacotherapy* **14**, 1467-1476 (2013).
11. Golomb, B.A., Kane, T. & Dimsdale, J.E. Severe irritability associated with statin cholesterol-lowering drugs. *Qjm-an International Journal of Medicine* **97**, 229-235 (2004).
12. Leuschen, J. *et al.* Association of Statin Use With Cataracts A Propensity Score-Matched Analysis. *Jama Ophthalmology* **131**, 1427-1434 (2013).
13. Ishida, J., Konishi, M., Ebner, N. & Springer, J. Repurposing of approved cardiovascular drugs. *Journal of Translational Medicine* **14**(2016).
14. Malfitano, A.M. *et al.* Statins in neurological disorders: An overview and update. *Pharmacological Research* **88**, 74-83 (2014).
15. Hennessy, E., Adams, C., Reen, F.J. & O'Gara, F. Is There Potential for Repurposing Statins as Novel Antimicrobials? *Antimicrobial Agents and Chemotherapy* **60**, 5111-5121 (2016).
16. Didelez, V. & Sheehan, N. Mendelian randomization as an instrumental variable approach to causal inference. *Statistical Methods in Medical Research* **16**, 309-330 (2007).
17. Benn, M. Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study (vol 357, j1648, 2017). *Bmj-British Medical Journal* **357**(2017).
18. Schmidt, A.F. *et al.* PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation

- study. *Lancet Diabetes & Endocrinology* **5**, 97-105 (2017).
19. Ference, B.A. *et al.* Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. *New England Journal of Medicine* **375**, 2144-2153 (2016).
20. Ference, B.A., Majeed, F., Penumetcha, R., Flack, J.M. & Brook, R.D. Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both. *Journal of the American College of Cardiology* **65**, 1552-1561 (2015).
21. Lotta, L.A. *et al.* Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes A Meta-analysis. *Jama-Journal of the American Medical Association* **316**, 1383-1391 (2016).
22. Bennett, D.A. & Holmes, M.V. Mendelian randomisation in cardiovascular research: an introduction for clinicians. *Heart* (2017).
23. Millard, L.A.C. *et al.* MR-PheWAS: hypothesis prioritization among potential causal effects of body mass index on many outcomes, using Mendelian randomization. *Scientific Reports* **5**(2015).
24. Millwood, I.Y. *et al.* A phenome-wide association study of a lipoprotein-associated phospholipase A(2) loss-of-function variant in 90 000 Chinese adults. *International Journal of Epidemiology* **45**, 1588-1599 (2016).
25. Walker, V.M., Smith, G.D., Davies, N.M. & Martin, R.M. Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities. *bioRxiv*, 105338 (2017).
26. Willer, C.J. *et al.* Discovery and refinement of loci associated with lipid levels. *Nature Genetics* **45**, 1274-+ (2013).
27. Hemani, G. *et al.* MR-Base: a platform for systematic causal inference across the phenome using billions of genetic associations. *bioRxiv*, 078972 (2016).
28. Pilling, L.C. *et al.* Human longevity is influenced by many genetic variants: evidence from 75,000 UK Biobank participants. *Aging-Us* **8**, 547-563 (2016).
29. Marioni, R.E. *et al.* Genetic variants linked to education predict longevity. *Proceedings of the National Academy of Sciences of the United States of America* **113**, 13366-13371 (2016).
30. Burgess, S., Dudbridge, F. & Thompson, S.G. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. *Stat Med* **35**, 1880-906 (2016).
31. Burgess, S. & Bowden, J. Integrating summarized data from multiple genetic variants in Mendelian randomization: bias and coverage properties of inverse-variance weighted methods. *arXiv preprint arXiv:1512.04486* (2015).
32. Burgess, S., Zuber, V., Valdes-Marquez, E., Sun, B.B. & Hopewell, J.C. Mendelian randomization with fine-mapped genetic data: Choosing from large numbers of correlated instrumental variables. *Genet Epidemiol* **41**, 714-725 (2017).
33. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B-Methodological* **57**, 289-300 (1995).

34. Benjamini, Y. & Yekutieli, D. The control of the false discovery rate in multiple testing under dependency. *Annals of statistics*, 1165-1188 (2001).
35. Glickman, M.E., Rao, S.R. & Schultz, M.R. False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies. *J Clin Epidemiol* **67**, 850-7 (2014).
36. Burgess, S. & Davey Smith, G. Mendelian Randomization Implicates High-Density Lipoprotein Cholesterol-Associated Mechanisms in Etiology of Age-Related Macular Degeneration. *Ophthalmology* **124**, 1165-1174 (2017).
37. Muldoon, M.F., Manuck, S.B. & Matthews, K.A. Lowering Cholesterol Concentrations and Mortality - a Quantitative Review of Primary Prevention Trials. *British Medical Journal* **301**, 309-314 (1990).
38. Engelberg, H. Low Serum-Cholesterol and Suicide. *Lancet* **339**, 727-729 (1992).
39. Morgan, R.E., Palinkas, L.A., Barrettconnor, E.L. & Wingard, D.L. Plasma-Cholesterol and Depressive Symptoms in Older Men. *Lancet* **341**, 75-79 (1993).
40. Aijanseppa, S. *et al.* Serum cholesterol and depressive symptoms in elderly Finnish men. *International Journal of Geriatric Psychiatry* **17**, 629-634 (2002).
41. Vevera, J. *et al.* Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. *Psychiatry Research* **133**, 197-203 (2005).
42. Duits, N. & Bos, F.M. Depressive Symptoms and Cholesterol-Lowering Drugs. *Lancet* **341**, 114-114 (1993).
43. Kasslertaub, K.B., Woodward, T. & Markowitz, J.S. Depressive Symptoms and Pravastatin. *Lancet* **341**, 371-372 (1993).
44. Hyyppa, M.T., Kronholm, E., Virtanen, A., Leino, A. & Jula, A. Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial. *Psychoneuroendocrinology* **28**, 181-194 (2003).
45. Morales, K. *et al.* Simvastatin causes changes in affective processes in elderly volunteers. *Journal of the American Geriatrics Society* **54**, 70-76 (2006).
46. Shrivastava, S., Pucadyil, T.J., Paila, Y.D., Ganguly, S. & Chattopadhyay, A. Chronic Cholesterol Depletion Using Statin Impairs the Function and Dynamics of Human Serotonin(1A) Receptors. *Biochemistry* **49**, 5426-5435 (2010).
47. Majewska, M.D. Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance. *Prog Neurobiol* **38**, 379-95 (1992).
48. Tanaka, M. & Sokabe, M. Continuous de novo synthesis of neurosteroids is required for normal synaptic transmission and plasticity in the dentate gyrus of the rat hippocampus. *Neuropharmacology* **62**, 2373-2387 (2012).
49. Kohler-Forsberg, O., Gasse, C., Berk, M. & Ostergaard, S.D. Do Statins Have Antidepressant Effects? *Cns Drugs* **31**, 335-343 (2017).
50. Salagre, E., Fernandes, B.S., Dodd, S., Brownstein, D.J. & Berk, M. Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials. *J Affect Disord* **200**, 235-42 (2016).
51. O'Neil, A. *et al.* The impact of statins on psychological wellbeing: a systematic review and meta-analysis. *BMC Med* **10**, 154 (2012).

52. Weinbrenner, T. *et al.* Lipoprotein metabolism in patients with anorexia nervosa: a case-control study investigating the mechanisms leading to hypercholesterolaemia. *British Journal of Nutrition* **91**, 959-969 (2004).
53. Rigaud, D., Tallonneau, I. & Verges, B. Hypercholesterolaemia in anorexia nervosa: Frequency and changes during refeeding. *Diabetes & Metabolism* **35**, 57-63 (2009).
54. Keller, W.R. *et al.* A review of anti-inflammatory agents for symptoms of schizophrenia. *Journal of Psychopharmacology* **27**, 337-342 (2013).
55. Vincenzi, B. *et al.* A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: Effect on inflammation, psychopathology, cognition and lipid metabolism. *Schizophrenia Research* **159**, 395-403 (2014).
56. Chaudhry, I.B. *et al.* Add-on Clinical Effects of Simvastatin and Ondansetron in Patients with Schizophrenia Stabilized on Antipsychotic Treatment: Pilot Study. *European Psychiatry* **29**(2014).
57. Kaneita, Y., Uchiyama, M., Yoshiike, N. & Ohida, T. Associations of usual sleep duration with serum lipid and lipoprotein levels. *Sleep* **31**, 645-652 (2008).
58. Zhan, Y.Q., Chen, R.Q. & Yu, J.M. Sleep duration and abnormal serum lipids: the China Health and Nutrition Survey. *Sleep Medicine* **15**, 833-839 (2014).
59. Takada, M., Fujimoto, M., Yamazaki, K., Takamoto, M. & Hosomi, K. Association of Statin Use with Sleep Disturbances: Data Mining of a Spontaneous Reporting Database and a Prescription Database (vol 37, pg 421, 2014). *Drug Safety* **37**, 653-653 (2014).
60. Broncel, M. *et al.* Sleep changes following statin therapy: a systematic review and meta-analysis of randomized placebo-controlled polysomnographic trials. *Arch Med Sci* **11**, 915-26 (2015).
61. Gupta, A. *et al.* Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. *Lancet* **389**, 2473-2481 (2017).
62. Shepardson, N.E., Shankar, G.M. & Selkoe, D.J. Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. *Archives of neurology* **68**, 1239-1244 (2011).
63. Shepardson, N.E., Shankar, G.M. & Selkoe, D.J. Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. *Archives of neurology* **68**, 1385-1392 (2011).
64. Power, M.C., Weuve, J., Sharrett, A.R., Blacker, D. & Gottesman, R.F. Statins, cognition, and dementia-systematic review and methodological commentary. *Nature Reviews Neurology* **11**, 220-229 (2015).
65. McGuinness, B., Craig, D., Bullock, R. & Passmore, P. Statins for the prevention of dementia. *Cochrane Database of Systematic Reviews* (2016).
66. Selley, M.L. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. *Brain Research* **1037**, 1-6 (2005).
67. Undela, K., Gudala, K., Malla, S. & Bansal, D. Statin use and risk of Parkinson's disease: a meta-analysis of observational studies. *Journal of Neurology* **260**, 158-165 (2013).

68. Bai, S. *et al.* Statin Use and the Risk of Parkinson's Disease: An Updated Meta-Analysis. *Plos One* **11**(2016).
69. Sheng, Z.G., Jia, X.B. & Kang, M.N. Statin use and risk of Parkinson's disease: A meta-analysis. *Behavioural Brain Research* **309**, 29-34 (2016).
70. Richardson, K. *et al.* Statins and Cognitive Function. *Annals of Internal Medicine* **159**, 688-+ (2013).
71. Ferket, B.S. *et al.* Personalized Prediction of Lifetime Benefits with Statin Therapy for Asymptomatic Individuals: A Modeling Study. *Plos Medicine* **9**(2012).
72. Mundy, G. *et al.* Stimulation of bone formation in vitro and in rodents by statins. *Science* **286**, 1946-1949 (1999).
73. Jadhav, S.B. & Jain, G.K. Statins and osteoporosis: new role for old drugs. *Journal of Pharmacy and Pharmacology* **58**, 3-18 (2006).
74. Wang, Z.Z., Li, Y., Zhou, F.X., Piao, Z. & Hao, J. Effects of Statins on Bone Mineral Density and Fracture Risk A PRISMA-compliant Systematic Review and Meta-Analysis. *Medicine* **95**(2016).
75. Sikora, J. *et al.* Effect of statins on platelet function in patients with hyperlipidemia. *Archives of Medical Science* **9**, 622-628 (2013).
76. Sivri, N. *et al.* Statins decrease mean platelet volume irrespective of cholesterol lowering effect. *Kardiol Pol* **71**, 1042-7 (2013).
77. Thaulow, E., Erikssen, J., Sandvik, L., Stormorken, H. & Cohn, P.F. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. *Circulation* **84**, 613-7 (1991).
78. Raki, M., Molberg, O., Tollefsen, S., Lundin, K.E. & Sollid, L.M. The effects of atorvastatin on gluten-induced intestinal T cell responses in coeliac disease. *Clin Exp Immunol* **142**, 333-40 (2005).
79. Palmer, S.C. *et al.* HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. *Sao Paulo Medical Journal* **133**, 541-542 (2015).
80. Sanguaneko, A., Upala, S., Cheungpasitporn, W., Ungprasert, P. & Knight, E.L. Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. *PLoS One* **10**, e0132970 (2015).
81. Boudreau, D.M., Yu, O. & Johnson, J. Statin use and cancer risk: a comprehensive review. *Expert Opinion on Drug Safety* **9**, 603-621 (2010).
82. Bonovas, S. Statins: Do They Have a Potential Role in Cancer Prevention and Modifying Cancer-Related Outcomes? *Drugs* **74**, 1841-1848 (2014).
83. Ulivieri, C. & Baldari, C.T. Statins: From cholesterol-lowering drugs to novel immunomodulators for the treatment of Th17-mediated autoimmune diseases. *Pharmacological Research* **88**, 41-52 (2014).
84. John, S.G., Thorn, J. & Sobonya, R. Statins as a Potential Risk Factor for Autoimmune Diseases: A Case Report and Review. *American Journal of Therapeutics* **21**, E94-E96 (2014).
85. Stancu, C. & Sima, A. Statins: mechanism of action and effects. *Journal of Cellular and Molecular Medicine* **5**, 378-387 (2001).
86. Paternoster, L., Tilling, K.M. & Smith, G.D. Genetic Epidemiology And Mendelian Randomization For Informing Disease Therapeutics: Conceptual And Methodological Challenges. *bioRxiv*, 126599

- (2017).
87. Naci, H. *et al.* Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. *European Journal of Preventive Cardiology* **20**, 641-657 (2013).
 88. Munafo, M.R., Tilling, K., Taylor, A.E., Evans, D.M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. *Int J Epidemiol* (2017).
 89. Fry, A. *et al.* Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. *Am J Epidemiol* **186**, 1026-1034 (2017).
 90. Okbay, A. *et al.* Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses. *Nat Genet* **48**, 624-33 (2016).
 91. Major Depressive Disorder Working Group of the Psychiatric, G.C. *et al.* A mega-analysis of genome-wide association studies for major depressive disorder. *Mol Psychiatry* **18**, 497-511 (2013).